Source: Annual Congress 2009 - Severe sepsis and multiple organ failure
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
V. K. Patil, J. B. Morjaria, F. DeVilliers, K. S. Babu (Nuneaton, Greenock, Salisbury, Bedford, United Kingdom). Procalcitonin as a diagnostic tool in systemic bacterial sepsis. Eur Respir J 2009; 34: Suppl. 53, 2799

Member's Comments

No comment yet.

Related content which might interest you: Procalcitonin has wider applicability in community-acquired pneumonia than other biomarkers Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018 Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy Source: Breathe, 15 (4) 296; 10.1183/20734735.0258-2019 Year: 2019 The role of Procalcitonin in management of pleural infections Source: International Congress 2019 – Pleural infection and complicated pneumonia Year: 2019 Usefulness of procalcitonin as a predictor for bacteremia and prognosis in severe sepsis Source: International Congress 2016 – Infections, sepsis, and pulmonary embolism Year: 2016 Procalcitonin to complement microbiology in LRTI and other infections Source: Annual Congress 2008 - Improved diagnosis and clinical decision-making by integrating information from new biomarkers Year: 2008 The diagnostic value of serum procalcitonin in differential diagnosis of pulmonary embolism and pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 462s Year: 2007 Serum Procalcitonin for diagnosing and monitoring response in pleural infection Source: International Congress 2019 – Pleural infection and complicated pneumonia Year: 2019 Usefulness of procalcitonin as a marker of bacterial inflammation in patients with heart failure and suspected pneumonia in x-ray examination Source: Annual Congress 2010 - Respiratory system involvement in non-pulmonary disorders Year: 2010 Usefulness of C-reactive protein and procalcitonin in predicting mortality in community-acquired pneumonia Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008 Individual monitoring of procalcitonin and C-reactive protein levels as a criterion for cancel of antibiotic therapy in patients with severe community-acquired pneumonia Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013 Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia Source: Eur Respir J 2008; 31: 356-362 Year: 2008 Procalcitonin and C reactive protein as markers of treatment failure in community-acquired pneumonia Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia Year: 2006 Procalcitonin and D-dimer to predict prognosis and clinical outcomes in severe community-acquired pneumonia (SCAP) patients Source: Annual Congress 2012 - Respiratory infections: a clinical point of view Year: 2012 C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia Source: Eur Respir J 2010; 35: 805-811 Year: 2010 Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study Source: Eur Respir J 2009; 34: 1364-1375 Year: 2009 The comparison of diagnostic relevance of protein C, C-reactive protein and endothelin-1 for prediction of lung vessel thrombosis in patients with community-acquired pneumonia Source: International Congress 2019 – Complex respiratory infections in clinical practice Year: 2019 The study of the role of procalcitonin (PCT) in early detection of nosocomial infections in chest patients Source: Annual Congress 2008 - Mechanical ventilation and airway management Year: 2008 Serum procalcitonin (PCT-Q) as a diagnostic tool for bacterial lower respiratory tract infection among COPD patients with acute exacerbation Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013